Pathogenesis and potential therapeutic application of stem cells transplantation in Huntington’s disease

Chen, 2016, Role of neuroinflammation in neurodegenerative diseases (Review), Mol Med Rep, 13, 3391, 10.3892/mmr.2016.4948 Akhtar, 2021, Neurodegenerative diseases and effective drug delivery: a review of challenges and novel therapeutics, J Contr Release, 330, 1152, 10.1016/j.jconrel.2020.11.021 Thomsen, 2014, The past, present and future of stem cell clinical trials for ALS, Exp Neurol, 262, 127, 10.1016/j.expneurol.2014.02.021 T, 2006, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, Cell, 126, 663, 10.1016/j.cell.2006.07.024 V, 1998, Huntington disease, J Neuropathol Exp Neurol, 57, 369, 10.1097/00005072-199805000-00001 1993, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group, Cell, 72, 971, 10.1016/0092-8674(93)90585-E S, 2013, CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease, J Med Genet, 50, 696, 10.1136/jmedgenet-2013-101796 H, 2018, Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities, Acta Pharmacol Sin, 39, 754, 10.1038/aps.2018.11 L, 2006, Expression and characterization of full-length human huntingtin, an elongated HEAT repeat protein, J Biol Chem, 281, 15916, 10.1074/jbc.M511007200 R, 2017, Post-translational modifications (PTMs), identified on endogenous huntingtin, cluster within proteolytic domains between HEAT repeats, J Proteome Res, 16, 2692, 10.1021/acs.jproteome.6b00991 D, 2016, Huntingtin N17 domain is a reactive oxygen species sensor regulating huntingtin phosphorylation and localization, Hum Mol Genet, 25, 3937, 10.1093/hmg/ddw234 G, 1999, Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology, J Neurosci, 19, 2522, 10.1523/JNEUROSCI.19-07-02522.1999 Vijayvargia, 2016, Huntingtin’s spherical solenoid structure enables polyglutamine tract-dependent modulation of its structure and function, Elife, 5, 10.7554/eLife.11184 V, 2015, Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspective, Mol Neurobiol, 51, 406, 10.1007/s12035-014-8715-8 G, 2006, Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin, Cell, 125, 1179, 10.1016/j.cell.2006.04.026 S, 2013, Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease, Proc Natl Acad Sci U S A, 110, 2366, 10.1073/pnas.1221891110 Lunkes, 2002, Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions, Mol Cell, 10, 259, 10.1016/S1097-2765(02)00602-0 T, 2002, Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain, J Neurochem, 82, 84, 10.1046/j.1471-4159.2002.00940.x W, 2002, Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease, J Neurosci, 22, 7862, 10.1523/JNEUROSCI.22-18-07862.2002 Luthi-Carter, 2000, Decreased expression of striatal signaling genes in a mouse model of Huntington's disease, Hum Mol Genet, 9, 1259, 10.1093/hmg/9.9.1259 Sipione, 2002, Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses, Human Molecular Genetics, 11, 312, 10.1093/hmg/11.17.1953 Nucifora, 2001, Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity, Science, 291, 2423, 10.1126/science.1056784 S, 2000, The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription, Proc Natl Acad Sci U S A, 97, 6763, 10.1073/pnas.100110097 M, 2001, Histone deacetylase inhibitors reduce polyglutamine toxicity, Proc Natl Acad Sci U S A, 98, 15179, 10.1073/pnas.261400698 Ferrante, 2003, Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice, Journal of Neuroscience, 23, 9418, 10.1523/JNEUROSCI.23-28-09418.2003 S, 2001, Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila, Nature, 413, 739, 10.1038/35099568 H, 2003, Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease, Proc Natl Acad Sci U S A, 100, 2041, 10.1073/pnas.0437870100 Jankovic, 2011, Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders, Expert Rev Neurother, 11, 1509, 10.1586/ern.11.149 Jankovic, 1988, Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias, Neurology, 38, 391, 10.1212/WNL.38.3.391 Grove, 2000, Improvement of Huntington's disease with olanzapine and valproate, N Engl J Med, 343, 973, 10.1056/NEJM200009283431316 Metman, 2002, Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine, Neurology, 59, 694, 10.1212/WNL.59.5.694 Lucetti, 2003, IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study, Neurology, 60, 1995, 10.1212/01.WNL.0000068165.07883.64 De Tommaso, 2007, Two years' follow-up of rivastigmine treatment in Huntington disease, Clin Neuropharmacol, 30, 43, 10.1097/01.wnf.0000240945.44370.f0 Patel, 1996, L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease, Ann Clin Psychiatr, 8, 23, 10.3109/10401239609149087 Andén, 1973, Baclofen and lithium in Huntington's chorea, Lancet, 2, 93, 10.1016/S0140-6736(73)93285-6 Curtis, 2006, Nabilone could treat chorea and irritability in Huntington's disease, J Neuropsychiatry Clin Neurosci, 18, 553, 10.1176/jnp.2006.18.4.553 Harding, 2018, Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities, Acta Pharmacol Sin, 39, 754, 10.1038/aps.2018.11 2006, Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial, Neurology, 66, 366, 10.1212/01.wnl.0000198586.85250.13 D, 2013, Cell therapy: the final frontier for treatment of neurological diseases, CNS Neurosci Ther, 19, 5, 10.1111/cns.12027 K, 2015, Neural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challenges, Stem Cell Res Ther, 6 LF, 2018, Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases, J Cell Physiol, 233, 3982, 10.1002/jcp.26192 C, 2018, Concise review: the use of stem cells for understanding and treating huntington's disease, Stem Cells, 36, 146, 10.1002/stem.2747 S, 2011, Mesenchymal stem cells neuronal differentiation ability: a real perspective for nervous system repair?, Curr Stem Cell Res Ther, 6, 82, 10.2174/157488811795495486 V, 2010, Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease, Transl Res, 155, 62, 10.1016/j.trsl.2009.07.006 Svendsen, 2000, Adult versus embryonic stem cells: which is the way forward?, Trends Neurosci, 23, 450, 10.1016/S0166-2236(00)01680-5 Rossignol, 2015, Reductions in behavioral deficits and neuropathology in the R6/2 mouse model of Huntington's disease following transplantation of bone-marrow-derived mesenchymal stem cells is dependent on passage number, Stem Cell Res Ther, 6, 10.1186/scrt545 Rossignol, 2011, Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington’s disease: morphological and behavioral outcomes, Behavioural Brain Research, 217, 369, 10.1016/j.bbr.2010.11.006 Jiang, 2013, 33, 331 Im, 2010, Transplantation of patient-derived adipose stem cells in YAC128 Huntington's disease transgenic mice, PLoS Curr, 2, 10.1371/currents.RRN1183 Qu, 2014, High-efficiency motor neuron differentiation from human pluripotent stem cells and the function of Islet-1, Nature Communications, 5, 10.1038/ncomms4449 DC, 2013, Human pluripotent stem cell differentiation into authentic striatal projection neurons, Stem Cell Rev Reports, 9, 461, 10.1007/s12015-013-9441-8 Al-Gharaibeh, 2017, Induced pluripotent stem cell-derived neural stem cell transplantations reduced behavioral deficits and ameliorated neuropathological changes in YAC128 mouse model of huntington's disease, Front Neurosci, 628, 10.3389/fnins.2017.00628 J, 2012, Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells, Stem Cells, 30, 2054, 10.1002/stem.1135 Meshorer, 2020, What are embryonic stem cells and how can they help us?, Front Young Minds, 8, 10.3389/frym.2020.00032 Li, 1998, Generation of purified neural precursors from embryonic stem cells by lineage selection, Curr Biol, 8, 971, 10.1016/S0960-9822(98)70399-9 Song, 2007, Human embryonic stem cell-derived neural precursor transplants attenuate apomorphine-induced rotational behavior in rats with unilateral quinolinic acid lesions, Neurosci Lett, 423, 58, 10.1016/j.neulet.2007.05.066 Neural stem cell | biology | Britannica n.d https://www.britannica.com/science/neural-stem-cell (Accessed April 18, 2022). Johann, 2007, Time of transplantation and cell preparation determine neural stem cell survival in a mouse model of Huntington's disease, Exp Brain Res, 177, 458, 10.1007/s00221-006-0689-y Ming, 2005, Adult neurogenesis in the mammalian central nervous system, Annu Rev Neurosci, 28, 223, 10.1146/annurev.neuro.28.051804.101459 Holley, 2018, Therapeutic effects of stem cells in rodent models of Huntington's disease: review and electrophysiological findings, CNS Neurosci Ther, 24, 329, 10.1111/cns.12839 Mangiarini, 1996, Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice, Cell, 87, 493, 10.1016/S0092-8674(00)81369-0 Pollock, 2016, Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in huntington's disease mouse models, Mol Ther, 24, 965, 10.1038/mt.2016.12 An, 2012, Genetic correction of huntington's disease phenotypes in induced pluripotent stem cells, Cell Stem Cell, 11, 253, 10.1016/j.stem.2012.04.026 Lee, 2009, Slowed progression in models of Huntington disease by adipose stem cell transplantation, Ann Neurol, 66, 671, 10.1002/ana.21788 El-Akabawy, 2012, Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease, BMC Neurosci, 13, 97, 10.1186/1471-2202-13-97 S, 1999, Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin, Hum Mol Genet, 8, 397 Zimmermann, 2016, ESC-derived BDNF-overexpressing neural progenitors differentially promote recovery in huntington's disease models by enhanced striatal differentiation, Stem Cell Rep, 7, 693, 10.1016/j.stemcr.2016.08.018 Ebert, 2010, Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease, Exp Neurol, 224, 155, 10.1016/j.expneurol.2010.03.005 Slow, 2003, Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease, Hum Mol Genet, 12, 1555, 10.1093/hmg/ddg169 Im, 2010, Transplantation of patient-derived adipose stem cells in YAC128 Huntington's disease transgenic mice, PLoS Curr, 2, 10.1371/currents.RRN1183 Al-Gharaibeh, 2017, Induced pluripotent stem cell-derived neural stem cell transplantations reduced behavioral deficits and ameliorated neuropathological changes in YAC128 mouse model of Huntington's disease, Front Neurosci, 11, 10.3389/fnins.2017.00628 Menalled, 2003, Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats, J Comp Neurol, 465, 11, 10.1002/cne.10776 Reidling, 2018, Human neural stem cell transplantation rescues functional deficits in R6/2 and Q140 huntington's disease mice, Stem Cell Rep, 10, 58, 10.1016/j.stemcr.2017.11.005 Shear, 1998, Chronic administration of quinolinic acid in the rat striatum causes spatial learning deficits in a radial arm water maze task, Exp Neurol, 150, 305, 10.1006/exnr.1998.6767 Jeon, 2012, Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells, Stem Cells, 30, 2054, 10.1002/stem.1135 Lescaudron, 2003, Autologous adult bone marrow stem cell transplantation in an animal model of huntington's disease: behavioral and morphological outcomes, Int J Neurosci, 113, 945, 10.1080/00207450390207759 Carpenter, 1997, Generation and transplantation of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice, Exp Neurol, 148, 187, 10.1006/exnr.1997.6657 Borlongan, 1997, 3-Nitropropionic acid animal model and Huntington's disease, Neurosci Biobehav Rev, 21, 289, 10.1016/S0149-7634(96)00027-9 Rossignol, 2011, Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes, Behav Brain Res, 217, 369, 10.1016/j.bbr.2010.11.006 Ryu, 2004, Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease, Neurobiol Dis, 16, 68, 10.1016/j.nbd.2004.01.016